{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=47", "query": { "intervention": "SC", "page": 47 }, "page_size": 10 }, "pagination": { "page": 47, "page_size": 10, "total_count": 3862, "total_pages": 387, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=48&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=46&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T16:33:33.214Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06450639", "title": "A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Duchenne Muscular Dystrophy" ], "interventions": [ { "name": "Satralizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "17 Years", "sex": "MALE", "summary": "8 Years to 17 Years · Male only" }, "enrollment_count": 30, "start_date": "2025-04-04", "completion_date": "2026-11-18", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-31T16:33:33.214Z", "location_count": 6, "location_summary": "Little Rock, Arkansas • Sacramento, California • Atlanta, Georgia + 3 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Sacramento", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Flower Mound", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06450639" }, { "nct_id": "NCT02500407", "title": "A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphocytic Leukemia, Chronic", "Lymphoma, Non Hodgkin" ], "interventions": [ { "name": "BTCT4465A (Mosunetuzumab) IV", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "BTCT4465A (Mosunetuzumab) SC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 713, "start_date": "2015-09-15", "completion_date": "2025-09-01", "has_results": false, "last_update_posted_date": "2025-09-12", "last_synced_at": "2026-10-31T16:33:33.214Z", "location_count": 12, "location_summary": "La Jolla, California • Santa Barbara, California • Denver, Colorado + 9 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02500407" }, { "nct_id": "NCT02552212", "title": "Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Axial Spondyloarthritis", "Nonradiographic Axial Spondyloarthritis", "Nr-axSpA" ], "interventions": [ { "name": "Certolizumab Pegol", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "UCB BIOSCIENCES GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 317, "start_date": "2015-09", "completion_date": "2020-05", "has_results": true, "last_update_posted_date": "2022-08-18", "last_synced_at": "2026-10-31T16:33:33.214Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Palm Desert", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02552212" }, { "nct_id": "NCT05660967", "title": "Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Epcoritamab", "type": "BIOLOGICAL" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "75 Years", "maximum_age": null, "sex": "ALL", "summary": "75 Years and older" }, "enrollment_count": 111, "start_date": "2023-03-06", "completion_date": "2026-06-10", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-31T16:33:33.214Z", "location_count": 1, "location_summary": "Waukesha, Wisconsin", "locations": [ { "city": "Waukesha", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05660967" }, { "nct_id": "NCT01350232", "title": "Treatment of Sickle Cell Anemia With Stem Cell Transplant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Sickle Cell Anemia", "Sickle Cell-hemoglobin C Disease", "Sickle Cell-β0-thalassemia" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Cellular Infusions", "type": "DEVICE" }, { "name": "Total Body Irradiation", "type": "RADIATION" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Plasmapheresis", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "DEVICE", "RADIATION", "PROCEDURE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 2, "start_date": "2009-09", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2025-05-16", "last_synced_at": "2026-10-31T16:33:33.214Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01350232" }, { "nct_id": "NCT05395481", "title": "A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metabolic Dysfunction-Associated Steatohepatitis (MASH)", "Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)" ], "interventions": [ { "name": "LY3849891", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 115, "start_date": "2022-06-08", "completion_date": "2026-05-12", "has_results": false, "last_update_posted_date": "2026-06-24", "last_synced_at": "2026-10-31T16:33:33.214Z", "location_count": 13, "location_summary": "Chandler, Arizona • Orange, California • Rialto, California + 8 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Rialto", "state": "California" }, { "city": "Brandon", "state": "Florida" }, { "city": "Maitland", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05395481" }, { "nct_id": "NCT07795164", "title": "Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metabolic Dysfunction-Associated Steatohepatitis (MASH)" ], "interventions": [ { "name": "Pemvidutide", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Altimmune, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1800, "start_date": "2026-07-30", "completion_date": "2032-12", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-31T16:33:33.214Z", "location_count": 9, "location_summary": "North Little Rock, Arkansas • Fountain Valley, California • Fresno, California + 6 more", "locations": [ { "city": "North Little Rock", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Gardena", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07795164" }, { "nct_id": "NCT07499232", "title": "A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Crohn Disease" ], "interventions": [ { "name": "Guselkumab", "type": "DRUG" }, { "name": "Risankizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 530, "start_date": "2026-04-21", "completion_date": "2030-12-11", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-31T16:33:33.214Z", "location_count": 39, "location_summary": "Dothan, Alabama • Mobile, Alabama • Anaheim, California + 32 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Los Alamitos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07499232" }, { "nct_id": "NCT07413939", "title": "RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "HER2-positive Breast Cancer" ], "interventions": [ { "name": "RO7771950", "type": "DRUG" }, { "name": "Tucatinib", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 650, "start_date": "2026-05-21", "completion_date": "2032-09-29", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-31T16:33:33.214Z", "location_count": 14, "location_summary": "Huntsville, Alabama • Gilbert, Arizona • San Francisco, California + 10 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Norwich", "state": "Connecticut" }, { "city": "East Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT07413939" }, { "nct_id": "NCT02593331", "title": "Study to Evaluate Safety, Tolerability, and Pharmacokinetics of BFKB8488A in Otherwise Healthy Overweight and Obese Participants With Likely Insulin Resistance", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Insulin Resistance" ], "interventions": [ { "name": "BFKB8488A", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 79, "start_date": "2015-10-29", "completion_date": "2017-03-28", "has_results": false, "last_update_posted_date": "2018-05-01", "last_synced_at": "2026-10-31T16:33:33.214Z", "location_count": 1, "location_summary": "Chula Vista, California", "locations": [ { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02593331" } ] }